Evidence map›Paper›PMID 32678217›Full record

ArticleScientific reports2020

Investigation of molecular mechanisms of experimental compounds in murine models of chronic allergic airways disease using synchrotron Fourier-transform infrared microspectroscopy.

Nadia Mazarakis, Jitraporn Vongsvivut, Keith R Bambery, Katherine Ververis, Mark J Tobin, Simon G Royce, Chrishan S Samuel, Kenneth J Snibson, Paul V Licciardi, Tom C Karagiannis

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Nadia MazarakisEpigenomic Medicine Laboratory, Department of Diabetes, Central Clinical School, Monash University, Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
Jitraporn VongsvivutANSTO Australian Synchrotron, Clayton, VIC, 3168, Australia.
Keith R BamberyANSTO Australian Synchrotron, Clayton, VIC, 3168, Australia.
Katherine VerverisEpigenomic Medicine Laboratory, Department of Diabetes, Central Clinical School, Monash University, Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia.
Mark J TobinANSTO Australian Synchrotron, Clayton, VIC, 3168, Australia.
Simon G RoyceDepartment of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3168, Australia.
Chrishan S SamuelDepartment of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Clayton, VIC, 3168, Australia.
Kenneth J SnibsonFaculty of Veterinary and Agricultural Sciences, University of Melbourne, Parkville, VIC, 3010, Australia.
Paul V LicciardiMurdoch Children's Research Institute, Melbourne, VIC, 3004, Australia.
Tom C KaragiannisEpigenomic Medicine Laboratory, Department of Diabetes, Central Clinical School, Monash University, Alfred Centre, 99 Commercial Road, Melbourne, VIC, 3004, Australia. tom.karagiannis@monash.edu.
Monash University · AUUniversity of Melbourne · AUAustralian Nuclear Science and Technology Organisation · AUAustralian Synchrotron · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ovalbumin-induced (OVA) chronic allergic airways murine model is a well-established model for investigating pre-clinical therapies for chronic allergic airways diseases, such as asthma. Here, we examined the effects of several experimental compounds with potential anti-asthmatic effects including resveratrol (RV), relaxin (RLN), L-sulforaphane (LSF), valproic acid (VPA), and trichostatin A (TSA) using both a prevention and reversal model of chronic allergic airways disease. We undertook a novel analytical approach using focal plane array (FPA) and synchrotron Fourier-transform infrared (S-FTIR) microspectroscopic techniques to provide new insights into the mechanisms of action of these experimental compounds. Apart from the typical biological effects, S-FTIR microspectroscopy was able to detect changes in nucleic acids and protein acetylation. Further, we validated the reduction in collagen deposition induced by each experimental compound evaluated. Although this has previously been observed with conventional histological methods, the S-FTIR technique has the advantage of allowing identification of the type of collagen present. More generally, our findings highlight the potential utility of S-FTIR and FPA-FTIR imaging techniques in enabling a better mechanistic understanding of novel asthma therapeutics.

Indexed as

AnimalsAnti-Asthmatic AgentsAsthmaChronic DiseaseDisease Models, AnimalDrug Evaluation, PreclinicalFemaleHydroxamic AcidsIsothiocyanatesMiceMice, Inbred BALB COvalbuminRelaxinResveratrolSpectroscopy, Fourier Transform InfraredSulfoxidesAnti-Asthmatic AgentsHydroxamic AcidsIsothiocyanatesOvalbuminRelaxinResveratrolsulforaphaneSulfoxidestrichostatin AValproic Acid

Identifiers

PMID32678217
PMCPMC7366655
OpenAlexW3043129617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.